Eli Lilly, Innovent's PD-1 in troubled waters as FDA review, oncology chief's...

[cafead]

via An FDA rebuff looks almost certain for Eli Lilly and partner Innovent Biologics’ PD-1 inhibitor Tyvyt as an overwhelmingly negative internal FDA review ahead of an advisory committee meeting suggests the agency is unwilling to consider a drug solely based on clinical data from China.

article source